Core Viewpoint - Bath & Body Works, Inc. is facing a class action lawsuit due to significant declines in financial performance and misleading statements regarding its business strategy and growth prospects during the Class Period from June 4, 2024, to November 19, 2025 [1][6]. Financial Performance - On August 28, 2025, Bath & Body Works reported Q2 2025 earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year, missing guidance by $0.03 [2]. - On November 20, 2025, the company reported Q3 2025 revenue declined by 1% year over year, net income fell 26% to $77 million, and full year guidance for net sales was cut from a positive 1.5%-2.7% to a negative "high single digits" [4]. Stock Price Reaction - Following the Q2 results on August 28, 2025, Bath & Body Works' stock price fell by $2.18, or 6.9%, closing at $29.36 per share [3]. - After the Q3 results on November 20, 2025, the stock price dropped by $5.22, or 24.8%, closing at $15.82 per share [5]. Business Strategy and Misleading Statements - The lawsuit alleges that the company misled investors by failing to disclose that its strategy of "adjacencies, collaborations and promotions" was ineffective in growing the customer base and that it relied on brand collaborations to mask weak financial results [6]. - The company admitted that its previous strategy had not been successful and announced a shift to focus on core categories instead of adjacencies [4].

If you purchased or otherwise acquired agilon securities during the Class Period, you may move the Court no later than March 2, 2026 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming March 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired agilon health, inc. ("agil ...

Core Viewpoint - Perrigo Company plc is facing a class action lawsuit due to alleged securities fraud related to its infant formula business, which has experienced significant operational challenges and financial underperformance since its acquisition of Nestlé's Gateway infant formula plant [11]. Group 1: Acquisition and Financial Performance - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - The company reported fiscal year 2023 earnings on February 27, 2024, indicating a 50% decline in earnings per share compared to the previous year, attributed to remediation costs in the infant formula business [4]. - Following the earnings report, Perrigo's share price dropped by $4.87, or 15.14%, closing at $27.30 on February 27, 2024 [5]. Group 2: Ongoing Challenges and Market Reactions - On May 7, 2024, Perrigo reported a 34.5% decrease in net sales to $91 million for the first quarter, alongside a decline in gross margin [6]. - The share price fell by $3.28, or 9.8%, to close at $30.15 on May 7, 2024, following this announcement [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price drop of $3.01, or 11.31%, to close at $23.61 [8]. Group 3: Strategic Review and Outlook Adjustments - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and revised its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The expected adjusted diluted earnings per share was also reduced to a range of $2.70 to $2.80, down from $2.90 to $3.10, indicating a significant cut in growth expectations [9]. - Following this news, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [10]. Group 4: Lawsuit Details - The class action lawsuit alleges that Perrigo made materially false and misleading statements regarding its business operations and failed to disclose significant issues within the acquired infant formula business [11]. - Specific allegations include underinvestment in maintenance and operational improvements, the need for substantial capital expenditures for remediation, and overstated financial results [11]. - Investors who purchased Perrigo securities during the class period are encouraged to participate in the lawsuit, with a deadline to file a lead plaintiff motion by January 16, 2026 [12].

Core Points - The article highlights the upcoming January 5, 2026 deadline for investors to file a lead plaintiff motion in a class action lawsuit related to Six Flags Entertainment Corporation [1] Group 1 - The class action is on behalf of investors who purchased or acquired Six Flags common stock linked to the company's registration statement and prospectus [1] - The lawsuit is connected to the merger of Six Flags with Cedar Fair, L.P. that took place on July 1, 2024 [1]

Core Points - Rosen Law Firm is reminding purchasers or sellers of Cepton, Inc. common stock during the Class Period from July 29, 2024, to January 6, 2025, about the December 8, 2025, lead plaintiff deadline [1] - Investors who participated in the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Legal Action Details - A class action lawsuit has been filed against Cepton, Inc. for making materially false and misleading statements regarding its business and operations during the Class Period [5] - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] Next Steps for Investors - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7]

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. by Berger Montague on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025, alleging that the company misled investors regarding a contract with the U.S. Department of Defense's Transportation Command [1][3]. Group 1: Lawsuit Details - The lawsuit claims that KBR misrepresented its relationship with TRANSCOM and the status of a Global Household Goods Contract, despite TRANSCOM expressing serious concerns [3]. - On June 19, 2025, it was revealed that TRANSCOM was terminating the contract, leading to a significant drop in KBR's share price by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 2: Investor Information - Investors who purchased KBR securities during the class period have until November 18, 2025, to seek appointment as lead plaintiff representatives [2].

Core Points - RCI Hospitality Holdings is facing a class action lawsuit for investors who acquired its securities between December 15, 2021, and September 16, 2025 [1] - The deadline for investors to seek lead plaintiff appointment in this class action is November 20, 2025 [1] Company Summary - RCI Hospitality Holdings is identified as the company involved in the class action lawsuit [1] - The lawsuit pertains to securities acquired during a specified class period, indicating potential legal and financial implications for the company [1]

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and clinical trials, particularly related to the briquilimab drug product [3]. Group 1: Company Developments - On July 7, 2025, Jasper announced issues with a drug product lot used in its BEACON Study for Chronic Spontaneous Urticaria, leading to a significant stock price drop of $3.73, or 55.1%, closing at $3.04 per share [2]. - The company is halting the development of briquilimab for asthma and SCID, and is implementing cost-cutting measures, including potential restructuring, to extend its financial runway [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Jasper's management made materially false and misleading statements and failed to disclose critical information about the company's operational controls and the risks associated with its clinical trials [3]. - Specific allegations include the lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the company's regulatory and commercial prospects [3]. Group 3: Legal Actions - Investors who purchased Jasper securities during the class period from November 30, 2023, to July 3, 2025, have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - UroGen Pharma Ltd. faces a class action lawsuit following significant stock price declines due to the FDA's negative assessment of its drug application for UGN-102, which raised concerns about the drug's efficacy and study design [2][3][4]. Group 1: Company Overview - UroGen Pharma Ltd. is involved in the development of UGN-102, a drug intended for treating recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer [3]. - The company submitted a new drug application (NDA) for UGN-102, which was met with skepticism from the FDA regarding the sufficiency of the submitted data [2]. Group 2: FDA Findings - The FDA's briefing document indicated doubts about the effectiveness of UGN-102, citing the lack of a concurrent control arm in the ENVISION trial, making the primary endpoints difficult to interpret [2]. - The FDA had previously recommended a randomized trial design to UroGen but the company opted not to follow this guidance [2]. Group 3: Stock Price Impact - Following the FDA's briefing document release on May 16, 2025, UroGen's stock price dropped by $2.54, or 25.8%, closing at $7.31 per share [2]. - After the Oncologic Drugs Advisory Committee voted against the NDA on May 21, 2025, the stock fell further by $3.37, or 44.7%, closing at $4.17 per share [3]. Group 4: Lawsuit Details - The class action lawsuit alleges that UroGen made materially false and misleading statements regarding the effectiveness of UGN-102 and failed to disclose significant risks associated with the drug's approval process [4]. - Specific allegations include the inadequacy of the ENVISION clinical study design and the company's disregard for FDA recommendations, leading to a substantial risk of NDA rejection [4].